Top Biotech Stocks To Research - April 25th

Key Points

• Danaher (DHR), Vertex (VRTX), and Medpace (MEDP) were identified by MarketBeat's screener on April 25 as the biotech stocks to research after posting the highest dollar trading volume among biotech names in recent days.
• Danaher supplies bioprocess technologies, consumables and manufacturing services that support biologics development, analytical testing and large‑scale production.
• Vertex is a specialty biotech focused on cystic fibrosis therapies (e.g., TRIKAFTA/KAFTRIO), while Medpace is a contract research organization providing end‑to‑end clinical development, regulatory and laboratory services to drug and device sponsors.

Danaher, Vertex Pharmaceuticals, and Medpace are the three Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech stocks are shares of companies that research, develop and commercialize products based on biological science—most commonly drugs, gene therapies, vaccines and diagnostic tools. For investors they tend to be high-risk, high-reward assets whose prices are driven by clinical trial results, regulatory approvals, patent positions and long development timelines. These companies had the highest dollar trading volume of any Biotech stocks within the last several days.

Danaher (DHR)

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.

Read Our Latest Research Report on DHR

Vertex Pharmaceuticals (VRTX)

Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis (CF). It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age or older; SYMDEKO/SYMKEVI for people with CF for 6 years of age or older; ORKAMBI for CF patients 1 year or older; and KALYDECO for the treatment of patients with 1 year or older who have CF with ivacaftor.

Read Our Latest Research Report on VRTX

Medpace (MEDP)

Medpace Holdings, Inc. engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.

Read Our Latest Research Report on MEDP

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.